Novartis Raises 2026 Core Operating Income Guidance After Q3 Results
Novartis reported Q3 2026 net sales of $14.52 billion, up from $13.91 billion a year earlier. Operating profit fell 59.11% to $1.84 billion, including a $1.9 billion impairment charge related to del-desiran. The company maintained its net sales growth outlook.